Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
“Beyond one gene, one target: Next-generation precision oncology: Trends in Cancer.”
Title: Beyond one gene, one target: Next-generation precision oncology
Authors: Vivek Subbiah, Razelle Kurzrock
To which Razelle Kurzrock, Founding Director at Michels Rare Cancers Research Laboratories, added:
“Important read from Subbiah and me. Where did we get the idea that tumors with multiple drivers would be optimally impacted by targeting only one of them?”
Other articles featuring Vivek Subbiah and Razelle Kurzrock on OncoDaily.